xevinapant

Merck KGaA pens $855M upfront, biobucks pact with Debiopharm for next-gen cancer asset
Fierce Biotech
Mon, 03/1/21 - 10:32 am
Merck KGaA
Debiopharm
biobucks
Bavencio
Debio1143
xevinapant